Downloads: 127

Files in This Item:
File Description SizeFormat 
JAHA.119.013703.pdf2.6 MBAdobe PDFView/Open
Title: Prognostic Impact of Baseline Hemoglobin Levels on Long-Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions
Authors: Nagao, Kazuya
Watanabe, Hirotoshi  kyouindb  KAKEN_id  orcid (unconfirmed)
Morimoto, Takeshi
Inada, Tsukasa
Hayashi, Fujio
Nakagawa, Yoshihisa
Furukawa, Yutaka
Kadota, Kazushige
Akasaka, Takashi
Natsuaki, Masahiro
Kozuma, Ken
Tanabe, Kengo
Morino, Yoshihiro
Shiomi, Hiroki  kyouindb  KAKEN_id
Kimura, Takeshi
Author's alias: 渡部, 宏俊
塩見, 紘樹
木村, 剛
Keywords: hemoglobin
percutaneous coronary interventions
Issue Date: 19-Nov-2019
Publisher: Ovid Technologies (Wolters Kluwer Health)
Journal title: Journal of the American Heart Association
Volume: 8
Issue: 22
Thesis number: e013703
Abstract: Background: Association of baseline hemoglobin levels with long-term adverse events after percutaneous coronary interventions has not been yet thoroughly defined. We aimed to assess the clinical impact of baseline hemoglobin on long-term ischemic and bleeding risk after percutaneous coronary intervention. Methods and Results: Using the pooled individual patient-level data from the 3 percutaneous coronary intervention studies, we categorized 19 288 patients into 4 groups: high-normal hemoglobin (≥14.0 g/dL; n=7555), low-normal hemoglobin (13.0-13.9 g/dL in men and 12.0-13.9 g/dL in women; n=5303), mild anemia (11.0-12.9 g/dL in men and 11.0-11.9 g/dL in women; n=4117), and moderate/severe anemia (<11.0 g/dL; n=2313). Median follow-up duration was 3 years. Low-normal hemoglobin, mild anemia, and moderate/severe anemia correlated with significant excess risk relative to high-normal hemoglobin for GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Trial) moderate/severe bleeding, with adjusted hazard ratios of 1.22 (95% CI, 1.04-1.44), 1.73 (95% CI, 1.47-2.04), and 2.31 (95% CI, 1.92-2.78), respectively. Moderate/severe anemia also correlated with significant excess risk relative to high-normal hemoglobin for the ischemic composite end point of myocardial infarction/ischemic stroke (adjusted hazard ratio, 1.33; 95% CI, 1.11-1.60), whereas low-normal hemoglobin and mild anemia did not. However, the excess risk of low-normal hemoglobin, mild anemia, and moderate/severe anemia relative to high-normal hemoglobin remained significant for ischemic stroke and for mortality. Conclusions: Decreasing baseline hemoglobin correlated with incrementally higher long-term risk for major bleeding, ischemic stroke, and mortality after percutaneous coronary intervention. Even within normal range, lower baseline hemoglobin level correlated with higher ischemic and bleeding risk.
Rights: Copyright © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
DOI(Published Version): 10.1161/JAHA.119.013703
PubMed ID: 31701786
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.